Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00248482 · ClinicalTrials.gov registry record · Phase 2

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

Completed
Registry status
Phase 2
Development phase
6
Enrollment target
2
Study locations

NCT00248482: Completed Phase 2 study of Lung Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

NCT00248482 is a Phase 2 study of Lung Cancer that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 6 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00248482, a Phase 2 study of Lung Cancer, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
6 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving imatinib mesylate after irinotecan and cisplatin may keep the tumor from coming back. PURPOSE: This phase II trial is studying how well giving imatinib mesylate after irinotecan and cisplatin works in treating patients with extensive-stage small cell lung cancer.

Conditions Studied

Lung Cancer

Interventions

  • DRUG Cisplatin
  • DRUG irinotecan
  • DRUG Gleevec™

Study Locations (2)

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor
  • Barbara Ann Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2002-02
Est. Completion 2008-01
Phase Phase 2
Barbara Ann Karmanos Cancer Institute

139 total trials

What the finished NCT00248482 record still lists

NCT00248482 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.

NCT00248482 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT00248482 about?

NCT00248482 is a clinical study titled "Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividin...

What is the current status of trial NCT00248482?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2002-02. Estimated completion is 2008-01.

What conditions does trial NCT00248482 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00248482?

The interventions under investigation include: Cisplatin (DRUG), irinotecan (DRUG), Gleevec™ (DRUG).

Who is sponsoring clinical trial NCT00248482?

This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00248482 being conducted?

This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00248482's enrollment target sits among peer trials

6 404th of 409 higher than 3 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00248482, the US trial registry maintained by the National Library of Medicine. NCT00248482 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.